Literature DB >> 9227325

Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis.

A Kawakami1, K Eguchi, N Matsuoka, M Tsuboi, S Urayama, Y Kawabe, T Aoyagi, K Maeda, S Nagataki.   

Abstract

This paper describes the immunoregulatory effects of interleukin-10 (IL-10) on synovial cells in vitro. Synovial cells were cultured with IL-10 in the presence or absence of various cytokines. Following incubation, the costimulatory molecule expression on synovial cells and cytokine production in culture supernatants were analysed by an indirect immunofluorescence method and enzyme-linked immunosorbent assay, respectively. We also examined the effect of IL-10 on the function of synovial cells as antigen-presenting cells (APC). Synovial cells spontaneously express several kinds of costimulatory molecule and produce various kinds of cytokines. Stimulation of synovial cells with interferon-gamma (IFN-gamma), IL-1 beta, or 12-O-tetradecanoyl phorbol 13-acetate (TPA) markedly enhanced the expression of costimulatory molecules and cytokine production of these cells. Both spontaneous and up-regulated costimulatory molecule expression and cytokine production were significantly suppressed by the addition of IL-10. Autologous T-cell proliferation was stimulated by purified protein derivative (PPD) in IFN-gamma-treated synovial cells and treatment of these synovial cells with IL-10 also suppressed T-cell proliferation. Our results suggest that IL-10 has an inhibitory effect on synovial cells and is an important immunoregulatory component of the cytokine network in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9227325      PMCID: PMC1363855          DOI: 10.1046/j.1365-2567.1997.00244.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment.

Authors:  L P Hale; M E Martin; D E McCollum; J A Nunley; T A Springer; K H Singer; B F Haynes
Journal:  Arthritis Rheum       Date:  1989-01

2.  Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells.

Authors:  N Matsuoka; K Eguchi; A Kawakami; M Tsuboi; Y Kawabe; T Aoyagi; S Nagataki
Journal:  Clin Exp Immunol       Date:  1996-06       Impact factor: 4.330

Review 3.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

4.  The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium.

Authors:  M F Liu; H Kohsaka; H Sakurai; M Azuma; K Okumura; I Saito; N Miyasaka
Journal:  Arthritis Rheum       Date:  1996-01

5.  Elevated interleukin-10 levels in patients with rheumatoid arthritis.

Authors:  J J Cush; J B Splawski; R Thomas; J E McFarlin; H Schulze-Koops; L S Davis; K Fujita; P E Lipsky
Journal:  Arthritis Rheum       Date:  1995-01

6.  Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells.

Authors:  E Sugiyama; A Kuroda; H Taki; M Ikemoto; T Hori; N Yamashita; M Maruyama; M Kobayashi
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

7.  Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions.

Authors:  W D Xu; G S Firestein; R Taetle; K Kaushansky; N J Zvaifler
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

8.  Selective regulation of ICAM-1 and major histocompatibility complex class I and II molecule expression on epidermal Langerhans cells by some of the cytokines released by keratinocytes and T cells.

Authors:  C H Chang; M Furue; K Tamaki
Journal:  Eur J Immunol       Date:  1994-11       Impact factor: 5.532

9.  Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis.

Authors:  P Chomarat; J Banchereau; P Miossec
Journal:  Arthritis Rheum       Date:  1995-08

10.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?

Authors:  C Jorgensen; F Apparailly; J Sany
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

2.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 3.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

4.  Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

Authors:  Lazaro E Aira; Patricia Hernández; Dinorah Prada; Araceli Chico; Jorge A Gómez; Zuyén González; Karla Fuentes; Carmen Viada; Zaima Mazorra
Journal:  MAbs       Date:  2015-10-15       Impact factor: 5.857

5.  Nuclear factor-kappaB and caspases co-operatively regulate the activation and apoptosis of human macrophages.

Authors:  A Hida; A Kawakami; T Nakashima; S Yamasaki; H Sakai; S Urayama; H Ida; H Nakamura; K Migita; Y Kawabe; K Eguchi
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

Review 6.  The dual nature of interleukin-10 in pemphigus vulgaris.

Authors:  Michael Jeffrey Cho; Christoph T Ellebrecht; Aimee S Payne
Journal:  Cytokine       Date:  2014-11-22       Impact factor: 3.861

7.  Association of the -1082 G/A promoter polymorphism of interleukin-10 gene with the autoantibodies production in patients with rheumatoid arthritis.

Authors:  Petr Nemec; Monika Pavkova-Goldbergova; Jindra Gatterova; Zdenek Fojtik; Anna Vasku; Miroslav Soucek
Journal:  Clin Rheumatol       Date:  2009-03-24       Impact factor: 2.980

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.